PL 8177

Drug Profile

PL 8177

Alternative Names: PL-8177

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palatin Technologies
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Melanocortin type 1 receptor agonists; Melanocortin type 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Ulcerative colitis
  • Preclinical Inflammatory bowel diseases; Nephritis; Uveitis

Most Recent Events

  • 08 Feb 2018 PL 8177 is available for licensing as of 08 Feb 2018 https://www.palatin.com/research-focus/licensing-collaboration/
  • 05 Feb 2018 Phase-I clinical trials in Ulcerative colitis (In volunteers) in USA (SC)
  • 03 Jan 2018 Preclinical trials in Inflammatory bowel disease in USA (PO) before January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top